Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D, Hermansson E, Ouwens M, Singh B, Sharma A, Jackson D, Darken P, Marshall J, Bowen K, Müllerová H, Alcázar Navarrete B, Russell R, Han MK, Tansey-Dwyer D. Stolz D, et al. Among authors: bowen k. Curr Med Res Opin. 2023 Oct;39(10):1395-1405. doi: 10.1080/03007995.2023.2247969. Epub 2023 Aug 29. Curr Med Res Opin. 2023. PMID: 37583267 Free article.
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in COPD: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).
Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, Kisielewicz D, Mushunje A, Movitz C, Ojili N, Parikh H, Arya N, Bowen K, Patel M. Singh D, et al. Among authors: bowen k. Am J Respir Crit Care Med. 2024 Aug 30. doi: 10.1164/rccm.202312-2311OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39213002
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.
Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M. Muro S, et al. Among authors: bowen k. Int J Chron Obstruct Pulmon Dis. 2024 Dec 12;19:2729-2737. doi: 10.2147/COPD.S478349. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39691156 Free PMC article. Clinical Trial.
Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
Corren J, Menzies-Gow A, Bimmel J, McGuinness A, Almqvist G, Bowen K, Griffiths JM, Ponnarambil S, Bourdin A, Israel E, Colice G, Brightling CE, Wechsler ME; PATHWAY and NAVIGATOR study investigators. Corren J, et al. Among authors: bowen k. Immunotherapy. 2023 Nov;15(16):1327-1340. doi: 10.2217/imt-2023-0109. Epub 2023 Sep 29. Immunotherapy. 2023. PMID: 37772607 Free article. Review.
Anion Photoelectron Spectroscopy and Ab Initio Studies of the UF- Anion.
Tufekci BA, Foreman K, Romeu JGF, Dixon DA, Peterson KA, Cheng L, Bowen KH. Tufekci BA, et al. Among authors: bowen kh. J Phys Chem Lett. 2024 Dec 5;15(48):11932-11938. doi: 10.1021/acs.jpclett.4c02845. Epub 2024 Nov 21. J Phys Chem Lett. 2024. PMID: 39574013
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
Muro S, Kawayama T, Sugiura H, Seki M, Duncan EA, Bowen K, Marshall J, Megally A, Patel M. Muro S, et al. Among authors: bowen k. Respir Res. 2024 Aug 5;25(1):297. doi: 10.1186/s12931-024-02918-8. Respir Res. 2024. PMID: 39103901 Free PMC article. Clinical Trial.
527 results